In 1902, Bayliss and Starling made the first discovery of a hormone capable of stimulating pancreatic secretion, glucagon (Bayliss and Starling, 1902) (Figure 1B)
Treatment with liraglutide injection 1.2 mg and liraglutide injection 1.8 mg resulted in statistically significant reductions in HbA1c relative to sitagliptin 100 mg (Table 5)
Clinical trials included dietary guidance (500 calorie deficit) and exercise recommendations (150 minutes weekly)
Ferrannini E, Baldi S, Frascerra S, et al
Most made weight loss a primary objective, with more than three quarters achieving their goal
Dosing & Reconstitution Guide Dosing frequency (educational reference): Once weekly subcutaneous administration is commonly used in GLP-3style protocols because these peptides are discussed as having an extended duration of activity , allowing steady signaling across the week